{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:15:12Z","timestamp":1788840912171,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,10,24]],"date-time":"2021-10-24T00:00:00Z","timestamp":1635033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,24]],"date-time":"2021-10-24T00:00:00Z","timestamp":1635033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014584","name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014584","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Integrins may be involved in the metastatic spread of high-grade serous ovarian cancer (HGSOC) which determines the therapeutical approach and prognosis. We investigated the integrin expression in primary tumor and metastases of advanced HGSOC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The expression of integrin \u03b12, \u03b14, \u03b15, \u03b16, and \u03b21 was assessed by immunostaining in tumor samples of the ovary, omentum, and peritoneum of each patient. Differences in integrin expression among tumor localizations and their association with clinicopathological parameters were examined by Fisher\u2019s exact test. The impact of integrin expression on progression-free survival (PFS) and overall survival (OS) was examined by Cox regression and Kaplan\u2013Meier analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Hundred and thirteen tumor samples of 40 HGSOC patients were examined. The expression of the integrins did not differ between the three tumor localizations (all <jats:italic>p<\/jats:italic> values\u2009&gt;\u20090.05) with the exception of high expression of integrin \u03b14 in primary tumor and omentum (52.5% versus 47.5%, <jats:italic>p<\/jats:italic>\u2009=\u20090.008) and primary tumor and peritoneum (52.5% versus 47.5%, <jats:italic>p<\/jats:italic>\u2009=\u20090.050). High expression of integrin \u03b14 in peritoneum was associated with poorer PFS (HR 2.02 95% CI 1.01\u20134.05, <jats:italic>p<\/jats:italic>\u2009=\u20090.047), younger age (<jats:italic>p<\/jats:italic>\u2009=\u20090.047), and death (<jats:italic>p<\/jats:italic>\u2009=\u20090.046). Median PFS in patients with high expression of integrin \u03b14 was 13.00\u00a0months, whereas median PFS in patients without high expression of integrin \u03b14 was 21.00\u00a0months (<jats:italic>p<\/jats:italic>\u2009=\u20090.040). Expression of other integrins did not correlate with PFS or OS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Expression of integrin \u03b14 may be altered during the metastatic spread of HGSOC and affect prognosis, whereas expression of integrin \u03b12, \u03b15, \u03b16, and \u03b21 did not reveal any prognostic value.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00404-021-06281-7","type":"journal-article","created":{"date-parts":[[2021,10,24]],"date-time":"2021-10-24T13:02:31Z","timestamp":1635080551000},"page":"1291-1298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Role of integrins in the metastatic spread of high-grade serous ovarian cancer"],"prefix":"10.1007","volume":"305","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8012-5772","authenticated-orcid":false,"given":"Slavomir","family":"Krajnak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"J\u00e4kel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Ani\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Hasenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walburgis","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Johannes","family":"Battista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,24]]},"reference":[{"key":"6281_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"6281_CR2","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3322\/caac.21559","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM (2019) Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin 69:280\u2013304. https:\/\/doi.org\/10.3322\/caac.21559","journal-title":"CA Cancer J Clin"},{"key":"6281_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/jnci\/djy071","volume":"111","author":"LC Peres","year":"2019","unstructured":"Peres LC, Cushing-Haugen KL, Kobel M, Harris HR, Berchuck A, Rossing MA, Schildkraut JM, Doherty JA (2019) Invasive epithelial ovarian cancer survival by histotype and disease stage. J Natl Cancer Inst 111:60\u201368. https:\/\/doi.org\/10.1093\/jnci\/djy071","journal-title":"J Natl Cancer Inst"},{"key":"6281_CR4","doi-asserted-by":"publisher","first-page":"viii51","DOI":"10.1093\/annonc\/mdx441","volume":"28","author":"S Pignata","year":"2017","unstructured":"Pignata S, Cecere CS, Du Bois A, Harter P, Heitz F (2017) Treatment of recurrent ovarian cancer. Ann Oncol 28:viii51\u2013viii56. https:\/\/doi.org\/10.1093\/annonc\/mdx441","journal-title":"Ann Oncol"},{"key":"6281_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","volume":"34","author":"RJ Kurman","year":"2010","unstructured":"Kurman RJ, Shih Ie M (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34:433\u2013443. https:\/\/doi.org\/10.1097\/PAS.0b013e3181cf3d79","journal-title":"Am J Surg Pathol"},{"key":"6281_CR6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nrc1611","volume":"5","author":"H Naora","year":"2005","unstructured":"Naora H, Montell DJ (2005) Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer 5:355\u2013366. https:\/\/doi.org\/10.1038\/nrc1611","journal-title":"Nat Rev Cancer"},{"key":"6281_CR7","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/s0002-9440(10)65406-5","volume":"154","author":"K Lessan","year":"1999","unstructured":"Lessan K, Aguiar DJ, Oegema T, Siebenson L, Skubitz AP (1999) CD44 and beta1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells. Am J Pathol 154:1525\u20131537. https:\/\/doi.org\/10.1016\/s0002-9440(10)65406-5","journal-title":"Am J Pathol"},{"key":"6281_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1477-3163-6-11","volume":"6","author":"K Shield","year":"2007","unstructured":"Shield K, Riley C, Quinn MA, Rice GE, Ackland ML, Ahmed N (2007) Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J Carcinog 6:11. https:\/\/doi.org\/10.1186\/1477-3163-6-11","journal-title":"J Carcinog"},{"key":"6281_CR9","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/s0092-8674(02)00971-6","volume":"110","author":"RO Hynes","year":"2002","unstructured":"Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110:673\u2013687. https:\/\/doi.org\/10.1016\/s0092-8674(02)00971-6","journal-title":"Cell"},{"key":"6281_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4161\/cam.18702","volume":"6","author":"K Zhang","year":"2012","unstructured":"Zhang K, Chen J (2012) The regulation of integrin function by divalent cations. Cell Adh Migr 6:20\u201329. https:\/\/doi.org\/10.4161\/cam.18702","journal-title":"Cell Adh Migr"},{"key":"6281_CR11","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3390\/cancers11070978","volume":"11","author":"B Alday-Parejo","year":"2019","unstructured":"Alday-Parejo B, Stupp R, Ruegg C (2019) Are integrins still practicable targets for anti-cancer therapy? Cancers (Basel) 11:978. https:\/\/doi.org\/10.3390\/cancers11070978","journal-title":"Cancers (Basel)"},{"key":"6281_CR12","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.3390\/ijms17122037","volume":"17","author":"D Bianconi","year":"2016","unstructured":"Bianconi D, Unseld M, Prager GW (2016) Integrins in the spotlight of cancer. Int J Mol Sci 17:2037. https:\/\/doi.org\/10.3390\/ijms17122037","journal-title":"Int J Mol Sci"},{"key":"6281_CR13","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","volume":"177","author":"E Lengyel","year":"2010","unstructured":"Lengyel E (2010) Ovarian cancer development and metastasis. Am J Pathol 177:1053\u20131064. https:\/\/doi.org\/10.2353\/ajpath.2010.100105","journal-title":"Am J Pathol"},{"key":"6281_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/gb-2007-8-5-215","volume":"8","author":"Y Takada","year":"2007","unstructured":"Takada Y, Ye X, Simon S (2007) The integrins. Genome Biol 8:215. https:\/\/doi.org\/10.1186\/gb-2007-8-5-215","journal-title":"Genome Biol"},{"key":"6281_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3390\/cancers9070083","volume":"9","author":"M Kobayashi","year":"2017","unstructured":"Kobayashi M, Sawada K, Kimura T (2017) Potential of integrin inhibitors for treating ovarian cancer: a literature review. Cancers (Basel) 9:83. https:\/\/doi.org\/10.3390\/cancers9070083","journal-title":"Cancers (Basel)"},{"key":"6281_CR16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3390\/cancers9090116","volume":"9","author":"M Nieberler","year":"2017","unstructured":"Nieberler M, Reuning U, Reichart F, Notni J, Wester HJ, Schwaiger M, Weinmuller M, Rader A, Steiger K, Kessler H (2017) Exploring the role of RGD-recognizing integrins in cancer. Cancers (Basel) 9:116. https:\/\/doi.org\/10.3390\/cancers9090116","journal-title":"Cancers (Basel)"},{"key":"6281_CR17","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.3892\/ol.2016.4895","volume":"12","author":"MJ Battista","year":"2016","unstructured":"Battista MJ, Schmidt M, Jakobi S, Cotarelo C, Almstedt K, Heimes AS, Makris GM, Weyer V, Lebrecht A, Hoffmann G, Eichbaum M (2016) c-met is overexpressed in type I ovarian cancer: results of an investigative analysis in a cohort of consecutive ovarian cancer patients. Oncol Lett 12:2001\u20132007. https:\/\/doi.org\/10.3892\/ol.2016.4895","journal-title":"Oncol Lett"},{"key":"6281_CR18","first-page":"138","volume":"8","author":"W Remmele","year":"1987","unstructured":"Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138\u2013140","journal-title":"Pathologe"},{"key":"6281_CR19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3390\/biomedicines9030289","volume":"9","author":"K Dotzer","year":"2021","unstructured":"Dotzer K, Schluter F, Koch FEV, Brambs CE, Anthuber S, Frangini S, Czogalla B, Burges A, Werner J, Mahner S, Mayer B (2021) Integrin alpha2beta1 represents a prognostic and predictive biomarker in primary ovarian cancer. Biomedicines 9:289. https:\/\/doi.org\/10.3390\/biomedicines9030289","journal-title":"Biomedicines"},{"key":"6281_CR20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.semcancer.2015.08.004","volume":"35","author":"D Naci","year":"2015","unstructured":"Naci D, Vuori K, Aoudjit F (2015) Alpha2beta1 integrin in cancer development and chemoresistance. Semin Cancer Biol 35:145\u2013153. https:\/\/doi.org\/10.1016\/j.semcancer.2015.08.004","journal-title":"Semin Cancer Biol"},{"key":"6281_CR21","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/cbin.11261","volume":"44","author":"W Zheng","year":"2020","unstructured":"Zheng W, Ge D, Meng G (2020) Reversing microtubule-directed chemotherapeutic drug resistance by co-delivering alpha2beta1 inhibitor and paclitaxel with nanoparticles in ovarian cancer. Cell Biol Int 44:610\u2013620. https:\/\/doi.org\/10.1002\/cbin.11261","journal-title":"Cell Biol Int"},{"key":"6281_CR22","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1186\/1471-2407-10-459","volume":"10","author":"Y Su","year":"2010","unstructured":"Su Y, Zheng L, Wang Q, Bao J, Cai Z, Liu A (2010) The PI3K\/Akt pathway upregulates Id1 and integrin alpha4 to enhance recruitment of human ovarian cancer endothelial progenitor cells. BMC Cancer 10:459. https:\/\/doi.org\/10.1186\/1471-2407-10-459","journal-title":"BMC Cancer"},{"key":"6281_CR23","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ygyno.2013.12.031","volume":"132","author":"JM Scalici","year":"2014","unstructured":"Scalici JM, Harrer C, Allen A, Jazaeri A, Atkins KA, McLachlan KR, Slack-Davis JK (2014) Inhibition of alpha4beta1 integrin increases ovarian cancer response to carboplatin. Gynecol Oncol 132:455\u2013461. https:\/\/doi.org\/10.1016\/j.ygyno.2013.12.031","journal-title":"Gynecol Oncol"},{"key":"6281_CR24","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/0008-5472.CAN-07-5167","volume":"68","author":"K Sawada","year":"2008","unstructured":"Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, Jagadeeswaran S, Montag A, Becker A, Kenny HA, Peter ME, Ramakrishnan V, Yamada SD, Lengyel E (2008) Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res 68:2329\u20132339. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-5167","journal-title":"Cancer Res"},{"key":"6281_CR25","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.3892\/ol.2019.10056","volume":"17","author":"L Wei","year":"2019","unstructured":"Wei L, Yin F, Chen C, Li L (2019) Expression of integrin alpha-6 is associated with multi drug resistance and prognosis in ovarian cancer. Oncol Lett 17:3974\u20133980. https:\/\/doi.org\/10.3892\/ol.2019.10056","journal-title":"Oncol Lett"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-021-06281-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-021-06281-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-021-06281-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T10:13:48Z","timestamp":1650190428000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-021-06281-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,24]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["6281"],"URL":"https:\/\/doi.org\/10.1007\/s00404-021-06281-7","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,24]]},"assertion":[{"value":"24 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SK received speaker honoraria from Roche Pharma AG; research funding from Novartis and travel reimbursement from PharmaMar.  MS received personal fees from AstraZeneca, Eisai, Lilly, MSD, Novartis, Pantarhei Bioscience, Pfizer, Roche, and SeaGen outside the submitted work; institutional research funding from AstraZeneca, BioNTech, Eisai, Genentech, German Breast Group, Novartis, Palleos, Pantarhei Bioscience, Pierre-Fabre, and Roche; and travel reimbursement from Pfizer and Roche. AH received personal fees from AstraZeneca, Celgen, GSK, LEO Pharma, MedConcept GmbH, Med update GmbH, Medicultus, PharmaMar, Pfizer, Promedicis GmbH, Softconsult, Roche Pharma AG, Streamedup! GmbH, Tesaro Bio Germany GmbH. MJB received honoraria and travel reimbursement from Roche Pharma AG, Tesaro Bio GmbH, Glaxo Smith Kline, Clovis Oncology, Astra Zeneca, Pharma Mar GmbH, Celgene, Pierre-Fabre Pharma GmbH. All remaining authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Research Ethics Committee of the University Medical Center Mainz, Germany. Informed consent was obtained from all the patients, and all the clinical investigations were conducted according to the ethical and legal standards, and with the 1964 Helsinki Declaration and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent to participate in the study was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All participants consented to the publication of the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}